Veracyte Inc(VCYT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:28 PM ET (Korea 10/28 05:28)
Full metrics table
| Index | RUT | P/E | 35.67 | EPS (ttm) | 1.41 | Insider Own | 1.83% | Shs Outstand | 80.4M | Perf Week | 12.26% |
| Market Cap | 4.04B | Forward P/E | 25.87 | EPS next Y | 1.8% | Insider Trans | -14% | Shs Float | 78.9M | Perf Month | 11.17% |
| Enterprise Value | 3.60B | PEG | 4.71 | EPS next Q | 0.41 | Inst Own | 114.13% | Short Float | 12.44% | Perf Quarter | -9.75% |
| Income | 0.11B | P/S | 7.19 | EPS this Y | 7.28% | Inst Trans | 2.8% | Short Ratio | 7.21 | Perf Half Y | 50.4% |
| Sales | 0.56B | P/B | 2.91 | EPS next 5Y | 5.49% | ROA | 8.09% | Short Interest | 9.82M | Perf YTD | 19.43% |
| Book/sh | 17.28 | P/C | 8.33 | EPS past 3/5Y | - | ROE | 8.77% | 52W High | -17.45% ($60.91) | Perf Year | 39.78% |
| Cash/sh | 6.04 | P/FCF | 24.35 | Sales past 3/5Y | 20.37% 34.5% | ROIC | 8.05% | 52W Low | 70.7% ($29.45) | Perf 3Y | 154.97% |
| Dividend Est. | - | EV/EBITDA | 30.58 | EPS Y/Y TTM | 323.64% | Gross Margin | 71.08% | Volatility(W/M) | 5.49% 5.32% | Perf 5Y | 10.82% |
| Dividend TTM | - | EV/Sales | 6.4 | Sales Y/Y TTM | 17.28% | Oper. Margin | 17.22% | ATR (14) | 2.44 | Perf 10Y | 546.27% |
| Dividend Ex-Date | - | Quick Ratio | 8.8 | EPS Q/Q | 2584.8% | Profit Margin | 20.37% | RSI (14) | 65.5 | Recom | 1.31 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.16 | Sales Q/Q | 15.49% | SMA20 | 11.02% ($45.29) | Beta | 1.99 | Target Price | $57.82 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/11/4 | SMA50 | 14.63% ($43.86) | Rel Volume | 1.33 | Prev Close | $48.2 |
| Employees | 755 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 31.61% 3.96% | SMA200 | 17.74% ($42.7) | Avg Volume(3M) | 1.36M | Price | $50.28 |
| IPO | 2013/10/30 | Option/Short | Yes/Yes | Trades | 15889 | Volume | 1,808,361 | Change | 4.32% |
A diagnostic company providing genome-based cancer diagnostic testing. It offers genomic tests for cancer diagnosis and prognosis prediction, including thyroid, prostate, and lung cancers, and is growing through increased test volume and the launch of new tests. The company specializes in the genome-based cancer diagnostics field.
Over the past 1 year, roughly in the middle
17% below its 1-year high.
Traded more than usual. That is 133% of its average volume.
Next earnings report: November 4
7 days to go.
VCYT makes money exceptionally well
Of every $100 in sales, $17.22 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +7.3% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $2,587. Peers typically go for $2,775. Compared with its own 2-year average, it is 48% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +10.8%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 114.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #23 of 44 in the industry
Based on market cap of $4B.
FAQ
What kind of company is VCYT?
VCYT belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of VCYT?
The market cap of VCYT is approximately $4.0B, ranking 1,538 within its sector.
What is the P/E ratio of VCYT?
VCYT has a P/E ratio of approximately 35.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for VCYT?
VCYT has recorded a 52-week high of $60.91 and a low of $29.45.
